Real-world outcomes of nivolumab-AVD and brentuximab vedotin-AVD in paediatric and adult advanced-stage Hodgkin lymphoma.
Real-world data suggest nivolumab-based treatment and standard chemotherapy work comparably well for advanced Hodgkin lymphoma, with trade-offs worth monitoring.
Brentuximab vedotin (BV)-doxorubicin, vinblastine and dacarbazine (AVD) and nivolumab (N)-AVD have transformed the frontline treatment of advanced-stage Hodgkin lymphoma (HL), yet real-world comparative data remain limited. These real-world data demonstrate comparable survival between regimens, with numerically improved PFS supporting N-AVD as a frontline standard for advanced-stage HL; however, higher rates of neutropenia and infections warrant careful monitoring and consideration of growth factor prophylaxis.
What the study was
- Study design
- Multicenter retrospective cohort study
- Population
- Paediatric and adult advanced-stage Hodgkin lymphoma patients (n=646, 17 US centers)
- Sample size
- 646
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- British journal of haematology
Why it surfaced
Large multicenter real-world comparison of two frontline Hodgkin lymphoma regimens; informs clinical decision-making between immunotherapy and antibody-drug conjugate approaches.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.